Latest news with #LFST
Yahoo
12 hours ago
- Business
- Yahoo
LifeStance (LFST) Extends 4-Day Run on Strong Earnings
We recently published . LifeStance Health Group, Inc. (NASDAQ:LFST) is one of the best-performing stocks on Wednesday. LifeStance Health extended its winning streak to a fourth straight day on Wednesday, jumping 10.94 percent to close at $5.17 apiece after reporting a strong performance in the second quarter of the year. Based on its updated report, net loss narrowed by 84 percent to $3.8 million from $23.3 million in the same period last year. Revenues increased by 11 percent to $345.3 million from $312.3 million year-on-year on the back of a higher visit volume from net clinician growth. Clinician base ended at 7,708 during the period, an increase of 173 or 11 percent from the first quarter of the year. 'I am incredibly proud of the LifeStance team for the strong results achieved in the second quarter,' said LifeStance Health Group, Inc. (NASDAQ:LFST) CEO Dave Bourdon, underscoring the double-digit organic revenue growth and 10 percent adjusted EBITDA margin. Encouraged by the results, LifeStance Health Group, Inc. (NASDAQ:LFST) maintained its full-year revenue growth target of $1.4 billion to $1.44 billion, as well as adjusted EBITDA to $140 million to $150 million. 25 Best Online Psychology Degree Programs Heading Into 2024 For the third quarter of the year, total revenues were expected to grow between $345 million and $365 million, while adjusted EBITDA was pegged at $33 million to $39 million. While we acknowledge the potential of LFST as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
LifeStance Health Group (LFST) Reports Q2 Loss, Tops Revenue Estimates
LifeStance Health Group (LFST) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +66.67%. A quarter ago, it was expected that this outpatient mental health services provider would post a loss of $0.04 per share when it actually produced break-even earnings, delivering a surprise of +100%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. LifeStance Health, which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, posted revenues of $345.31 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.02%. This compares to year-ago revenues of $312.33 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. LifeStance Health shares have lost about 47.1% since the beginning of the year versus the S&P 500's gain of 7.9%. What's Next for LifeStance Health? While LifeStance Health has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for LifeStance Health was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.01 on $359.78 million in revenues for the coming quarter and -$0.06 on $1.42 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Outpatient and Home Healthcare is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, RadNet (RDNT), has yet to report results for the quarter ended June 2025. The results are expected to be released on August 10. This operator of medical diagnostic imaging centers is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of +6.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. RadNet's revenues are expected to be $488.57 million, up 6.3% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report LifeStance Health Group, Inc. (LFST) : Free Stock Analysis Report RadNet, Inc. (RDNT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
17-07-2025
- Business
- Yahoo
LifeStance to Host Second Quarter 2025 Earnings Conference Call on August 7, 2025
SCOTTSDALE, Ariz., July 17, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatient mental health care, will issue its second quarter 2025 earnings release before the market opens on Thursday, August 7, 2025. LifeStance will host a live earnings conference call to discuss second quarter results on August 7, 2025, at 8:30 a.m. Eastern Time. To participate in the call, please dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, and use conference ID 1294873, or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website ( where related materials will be posted prior to the conference call. A replay of the webcast will be available after the conclusion of the conference call and can be accessed on the LifeStance Investor Relations website. About LifeStance HealthFounded in 2017, LifeStance (NASDAQ: LFST) is reimagining mental health. We are one of the nation's largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental health care. LifeStance and its supported practices employ approximately 7,500 psychiatrists, advanced practice nurses, psychologists and therapists and operate across 33 states and more than 550 centers. To learn more, please visit CONTACT: Investor Contact: Monica Prokocki Vice President of Finance and Investor Relations Media Contact: Brooke Matthews Senior Director of Communications media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-06-2025
- Business
- Yahoo
LFST Q1 Earnings Call: Outpatient Behavioral Health Sees Stable Growth, Margin Improvement, and Shifts in Clinician Incentives
Behavioral health company LifeStance Health (NASDAQ:LFST) met Wall Street's revenue expectations in Q1 CY2025, with sales up 10.8% year on year to $333 million. Its non-GAAP profit of $0.05 per share was significantly above analysts' consensus estimates. Is now the time to buy LFST? Find out in our full research report (it's free). Revenue: $333 million vs analyst estimates of $333.5 million (10.8% year-on-year growth, in line) Adjusted EBITDA: $34.65 million vs analyst estimates of $30.19 million (10.4% margin, 14.7% beat) The company reconfirmed its revenue guidance for the full year of $1.42 billion at the midpoint EBITDA guidance for the full year is $140 million at the midpoint, in line with analyst expectations Operating Margin: 0.5%, up from -5.6% in the same quarter last year Market Capitalization: $2.29 billion LifeStance Health's first quarter performance was driven by steady clinician headcount growth and operational streamlining, as management emphasized progress on digital initiatives and improvements in patient collections. CEO David Bourdon highlighted that the company's hybrid care model, combining in-person and virtual visits, continues to support robust clinician recruitment and retention. Bourdon also pointed to the new digital patient check-in tool, stating it 'is driving higher patient satisfaction, operational efficiencies and significant improvements in patient collections.' The company's focus on refining its value proposition for clinicians led to the implementation of a new cash-based incentive program, replacing the prior stock-based approach. Management attributed improved profitability to both greater clinician productivity and incremental payer rate increases, while also noting that specialty services—such as neuropsychological testing and treatments for resistant depression—are expanding, albeit from a small base. Looking ahead, LifeStance Health's forward guidance is shaped by the absorption of a final rate decrease from a single payer, with management anticipating near-term pressure on per-visit revenue and margins, particularly in the next quarter. CFO Ryan McGroarty explained that 'the second quarter is the first full quarter in which we will be absorbing this impact,' leading to sequential declines in revenue per visit and adjusted EBITDA margins. Management expects revenue growth to be driven primarily by increased visit volumes and gradual rate improvements from other payers in the back half of the year. Bourdon emphasized confidence in the company's insurance-based model to weather economic uncertainty, adding, 'our model is resilient to economic cycles' and may even benefit from increased demand for mental health services in a downturn. The company also plans to resume its evaluation of a new electronic health record (EHR) platform, aiming to support clinician and patient experience improvements over the next several years. Management credited first quarter performance to clinician growth, operational standardization, and digital tool adoption, while margin improvement stemmed from both higher productivity and disciplined spending. Clinician headcount expansion: The clinician base grew by 152 in the quarter, totaling over 7,500. Management attributed this to the appeal of LifeStance's hybrid care model, which offers both virtual and in-person practice flexibility. This growth is seen as essential to meeting rising patient demand and supporting visit volume increases. Digital check-in tool rollout: The company completed the rollout of its digital patient check-in platform, which improved patient satisfaction and materially enhanced the collections process. Management stated that this was a primary driver behind the reduction in days sales outstanding (DSO) to 38 days, a company low. Shift to cash-based clinician incentives: Responding to clinician feedback, LifeStance replaced its stock-based incentive program with a cash bonus structure focused on quality and productivity. Management believes this will better align clinician interests with patient care goals and potentially support retention and recruitment. Specialty services expansion: The company is growing its specialty offerings in neuropsychological testing, transcranial magnetic stimulation (TMS), and Spravato for treatment-resistant depression. While currently about $50 million in revenue, management expects these services to outpace the core business in growth and deliver higher margins over time. Operational efficiencies and margin gains: LifeStance achieved its first-ever positive net income as a public company, which management credited to both higher clinician productivity and disciplined general and administrative spending. The company's adjusted EBITDA margin reached double digits for the second straight quarter, reflecting ongoing standardization and cost management. Management's guidance focuses on volume-driven growth, modest rate improvements, and a transition period as the company absorbs a payer rate decrease. Visit volume as growth engine: The company expects overall revenue expansion to be primarily driven by higher visit volumes, supported by both clinician headcount growth and efforts to better fill existing clinician calendars. Management cited this as the main path to sustained top-line increases in the near term. Payer rate dynamics and margin pressure: A final rate decrease from a single payer will weigh on revenue per visit and margins in the upcoming quarter. Management anticipates this headwind will be partially offset by modest rate increases from other payers and greater specialty service revenue in the second half of the year. Strategic focus on operational initiatives: The company is prioritizing the evaluation of a new EHR platform and the continued rollout of specialty services. Management believes these initiatives will improve operational efficiency, clinician and patient satisfaction, and support long-term margin expansion, but cautioned that benefits will accrue gradually over several years. In coming quarters, the StockStory team will monitor (1) how LifeStance navigates payer rate changes and their effect on per-visit revenue and margins, (2) the pace of clinician headcount and productivity growth, and (3) expansion of specialty service offerings and their contribution to overall revenue and margin mix. Execution on the EHR initiative and continued digital platform enhancements will also be important markers of progress. LifeStance Health Group currently trades at a forward P/E ratio of 77.5×. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Yahoo
28-05-2025
- Business
- Yahoo
UBS Sees Misunderstood Strength in Lifestance Health Group (LFST), Upgrades to Buy
UBS analyst Kevin Caliendo raised the rating of LifeStance Health Group, Inc. (NASDAQ:LFST) from Neutral to Buy on May 27, with an unchanged price target of $8.50. Caliendo ascribes the boost to investor de-risking and possible misunderstandings of recent corporate developments, which followed a period of downturn for the LFST stock. Despite a cautious forecast for the second quarter, LifeStance Health Group, Inc. (NASDAQ:LFST) reported a robust first quarter, exceeding projections, with adjusted EBITDA increasing 25% to $35 million and revenue rising 11% year-over-year to $333 million. In addition, Caliendo discussed the company's decision to switch from stock to cash incentives, which he views as an effective strategy that could yield LifeStance Health Group, Inc. (NASDAQ:LFST) over $40 million in net income yearly for the next four years. The analyst also brushed aside worries about the federal government's decision to suspend the mental health parity rule. He added that the company's reimbursement rates and rate-improvement track shouldn't be impacted by this suspension. LifeStance Health Group, Inc. (NASDAQ:LFST) is an American outpatient behavioral health service company that offers in-person and telehealth services. The company offers therapy, psychiatry, and TMS. While we acknowledge the potential of LFST to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LFST and that has 100x upside potential, check out our report about the cheapest AI stock. Read More: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
